Uncategorized

New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells

Published

on

Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version